Morgan Stanley Bio Affinity Technologies, Inc. Call Options Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding BIAF
# of Institutions
17Shares Held
536KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA261KShares$117,3910.0% of portfolio
-
Geode Capital Management, LLC Boston, MA99.6KShares$44,7970.0% of portfolio
-
Sheaff Brock Investment Advisors, LLC46.3KShares$20,8360.0% of portfolio
-
Captrust Financial Advisors Raleigh, NC27.9KShares$12,5480.0% of portfolio
-
State Street Corp Boston, MA17.6KShares$7,9200.0% of portfolio
About bioAffinity Technologies, Inc.
- Ticker BIAF
- Exchange
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 2,727,580
- Market Cap $1.23M
- Description
- bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is b...